Relevant bibliographies by topics / Chemotherapy. Perillyl alcohol

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Conference papers

Academic literature on the topic 'Chemotherapy. Perillyl alcohol'

Author: Grafiati
Published: 4 June 2021
Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Chemotherapy. Perillyl alcohol.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Chemotherapy. Perillyl alcohol"

1

Stark, M. Jennifer, Yvette D. Burke, Jamie H. McKinzie, A. Siar Ayoubi, and Pamela L. Crowell. "Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol." Cancer Letters 96, no. 1 (September 1995): 15–21. http://dx.doi.org/10.1016/0304-3835(95)03912-g.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

da Fonseca, ClovisOrlando, Himanshu Khandelia, MarcelaD'Alincourt Salazar, AxelH Schönthal, OsórioC Meireles, and Thereza Quirico-Santos. "Perillyl alcohol: Dynamic interactions with the lipid bilayer and implications for long-term inhalational chemotherapy for gliomas." Surgical Neurology International 7, no. 1 (2016): 1. http://dx.doi.org/10.4103/2152-7806.173301.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Santos, Juliana Guimaraes, Gisele Faria, Wanise Da Cruz Souza Da Cruz, Cristina Asvolinsque Fontes, Axel H. Schönthal, Thereza Quirico-Santos, and Clovis O. da Fonseca. "Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy." Surgical Neurology International 11 (November 11, 2020): 389. http://dx.doi.org/10.25259/sni_445_2020.

Full text
Abstract:
Background: Standard of care for glioblastoma (GB), consisting of cytotoxic chemotherapy, steroids, and high-dose radiation, induces changes in the tumor microenvironment through its effects on glucose availability, which is a determinant for tumor progression (TP). Low-carbohydrate diet (LCD) reduces the glucose levels needed to drive the Warburg effect. Methods: To investigate LCD’s effect on GB therapy, we have begun a clinical trial using LCD as an addition to intranasal perillyl alcohol (POH) for recurrent GB (rGB) patients. This study involved 29 individuals and evaluated, over a period of 1 year, the adjuvant effect of LCD associated with POH therapy in terms of toxicity, extent of peritumoral edema, reduced corticosteroid use, seizure frequency, and overall survival. POH group (n = 14) received solely intranasal POH without specific diet regimen, whereas POH/LCD group (n = 15) received intranasal POH in combination with nutritional intervention. Patients’ assessment was based on clinical reviews and magnetic resonance data. Results: In the 1-year follow-up, the POH/LCD group showed a 4.4-fold decrease in the proportion of patients who needed treatment with corticosteroids, as well as a reduction in tumor size and peritumoral edema, as compared to the POH group. While 75% of patients undergoing POH treatment experienced seizures, this fraction was reduced to 56% in the POH/LCD group. A 2.07-fold increase in the proportion of patients with stable disease, along with a 2.8-fold decrease in the proportion of patients with TP, was seen in the POH/LCD group. Conclusion: The results presented in this study show that the LCD associated with intranasal POH therapy may represent a viable option as adjunctive therapy for rGB to improve survival without compromising patients’ quality of life. Prospective cohort studies are needed to confirm these findings and validate the efficacy of this novel therapeutic strategy.
APA, Harvard, Vancouver, ISO, and other styles
4

Da Fonseca, C. O., and Gilberto Schwartsmann. "Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 14037. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14037.

Full text
Abstract:
14037 Background: Deregulated p21-Ras function, as a result of mutation, overexpresion or growth factor-induced overactivation, contributes to growth of malignant gliomas. Perillyl alcohol (POH) is a monoterpene with preclinical antitumor activity in several types of tumor in rodent models and is currently under phase I and phase II clinical trials. Its proposed mechanism of action involves inhibition of post- translational isoprenylation of small G proteins, including p21-Ras, thereby blocking signal transduction Methods: The intranasal delivery is a practical and non-invasive approach that allows therapeutic agents, which do not cross the blood brain barrier (BBB) to enter the Central Nervous System (CNS), reducing unwanted systemic side effects. Applying this method we performed a phase I / II study with POH intranasal administration in patients with relapsed malignant gliomas after standard treatment: surgery, radiotherapy and chemotherapy. POH was administrated in concentration 0.3% volume/volume (55mg) 4 times daily. Results: Thirty-seven patients enrolled being 29 with glioblastoma multiform (GBM), 5 with grade III astrocytoma (AA) and 3 with anaplastic oligodendroglioma (AO). The results showed that POH is well tolerated and display at 6 months of treatment partial responses in 1 patient (3,4%) with GBM and 1 patient (33,3%) with AO; stable disease in 13 patients (44,8%) with GBM, 3 patients (60%) with AA and 1 patient (33,3%) with AO; progressive response in 15 patient (51,7%) with GBM, 2 patients (40%) with AA e 1 patient (33,3%) with AO. Conclusions: The POH intranasal delivery in a concentration of 0.3% volume/volume (55 mg) is well tolerated, and may prolong survival in patients with relapsed malignant gliomas patients. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
5

Schönthal, Axel H., Steve Swenson, Radu O. Minea, Hye Na Kim, Heeyeon Cho, Nazleen Mohseni, Yong-Mi Kim, and Thomas C. Chen. "Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia." Cancers 13, no. 14 (July 6, 2021): 3385. http://dx.doi.org/10.3390/cancers13143385.

Full text
Abstract:
Despite progress in the treatment of acute myeloid leukemia (AML), the clinical outcome remains suboptimal and many patients are still dying from this disease. First-line treatment consists of chemotherapy, which typically includes cytarabine (AraC), either alone or in combination with anthracyclines, but drug resistance can develop and significantly worsen prognosis. Better treatments are needed. We are developing a novel anticancer compound, NEO212, that was created by covalent conjugation of two different molecules with already established anticancer activity, the alkylating agent temozolomide (TMZ) and the natural monoterpene perillyl alcohol (POH). We investigated the anticancer activity of NEO212 in several in vitro and in vivo models of AML. Human HL60 and U937 AML cell lines, as well as different AraC-resistant AML cell lines, were treated with NEO212 and effects on cell proliferation, cell cycle, and cell death were investigated. Mice with implanted AraC-sensitive or AraC-resistant AML cells were dosed with oral NEO212, and animal survival was monitored. Our in vitro experiments show that treatment of cells with NEO212 results in growth inhibition via potent G2 arrest, which is followed by apoptotic cell death. Intriguingly, NEO212 was equally potent in highly AraC-resistant cells. In vivo, NEO212 treatment strikingly extended survival of AML mice and the majority of treated mice continued to thrive and survive without any signs of illness. At the same time, we were unable to detect toxic side effects of NEO212 treatment. All in all, the absence of side effects, combined with striking therapeutic activity even in an AraC-resistant context, suggests that NEO212 should be developed further toward clinical testing.
APA, Harvard, Vancouver, ISO, and other styles
6

Sherman, Eric J., David M. Rubin, Ennapadam Venkatraman, Gary K. Schwartz, Vincent A. Miller, Mark H. Radzyner, Hirsch S. Ruchlin, David Spriggs, and David G. Pfister. "Using Patients As Their Own Controls for Cost Evaluation of Phase I Clinical Trials." Journal of Clinical Oncology 22, no. 7 (April 1, 2004): 1308–14. http://dx.doi.org/10.1200/jco.2004.06.118.

Full text
Abstract:
PurposeLittle is known about the cost of phase I trials in cancer patients compared with that of standard treatments, yet the former is often assumed to be greater than the latter. Our objective was to utilize a new approach, using patients as their own controls, to compare in a pilot study the costs of care for patients on phase I trials with those incurred for standard treatment.Patients and MethodsWe retrospectively assessed the direct medical costs (DMCs) of 59 patients participating in one of two phase I trials (TRIAL) in solid tumors conducted at Memorial Hospital (MH): (1) perillyl alcohol, and (2) flavopiridol with paclitaxel. Paired-control DMCs were those accrued by the same patient while receiving standard chemotherapy regimens just before (PRE; n = 41) or after (POST; n = 29) the trial at MH, averaged per day.ResultsFor the 41 PRE patients, the median and mean DMCs per day for the clinical trial versus standard treatment were (US $) $123 v $133 and $219 v $267, respectively. For the 29 POST patients, the median and mean DMCs for the clinical trial versus standard treatment were $157 v $152 and $226 v $226, respectively. Using a linear mixed model, there was no significant difference between TRIAL and standard treatment DMCs (P = .54).ConclusionUsing patients as their own controls represents a new, efficient method for evaluating the cost of phase I trials, and it warrants further study. The results of our pilot study do not suggest that phase I trials always cost payers more than standard treatment.
APA, Harvard, Vancouver, ISO, and other styles
7

Marín-Ramos, Nagore I., Marta Pérez-Hernández, Anson Tam, Stephen D. Swenson, Hee-Yeon Cho, Thu Zan Thein, Florence M. Hofman, and Thomas C. Chen. "Inhibition of motility by NEO100 through the calpain-1/RhoA pathway." Journal of Neurosurgery 133, no. 4 (October 2020): 1020–31. http://dx.doi.org/10.3171/2019.5.jns19798.

Full text
Abstract:
OBJECTIVEGlioblastoma (GBM) is the most aggressive type of brain tumor with a high rate of tumor recurrence, and it often develops resistance over time to current standard of care chemotherapy. Its highly invasive nature plays an essential role in tumor progression and recurrence. Glioma stem cells (GSCs) are a subpopulation of glioma cells highly resistant to treatments and are considered responsible for tumor recurrence.METHODSPatient-derived populations of GSCs were analyzed by western blot, MTT, and cytoplasmic calcium labeling to determine the cytotoxicity of NEO100. High-performance liquid chromatography was used to evaluate the levels of NEO100 in the cell culture supernatants. The effects of the compound on GSC motility were studied using Boyden chamber migration, 3D spheroid migration and invasion assays, and an mRNA expression PCR array. A RhoA activation assay, western blot, and immunofluorescence techniques were employed to confirm the signaling pathways involved. Intracranial implantation of GSCs in athymic mice was used to evaluate the effects of NEO100 in vivo on tumor progression and overall survival.RESULTSHere, the authors show how NEO100, a highly purified good manufacturing practices–quality form of perillyl alcohol, is cytotoxic for different subtypes of GSCs, regardless of the mechanisms of DNA repair present. At doses similar to the IC50 (half maximal inhibitory concentration) values, NEO100 induces ER stress and activates apoptotic pathways in all GSC populations tested. At subcytotoxic doses in the micromolar range, NEO100 blocks migration and invasion of GSCs. These results correlate with a decrease in calpain-1 expression and an increase in RhoA activation, leading to enhanced contractility of the GSCs. In addition, NEO100 blocks the activation of the kinases Src, p42/44 MAPK, Akt, and Stat3, all related to cell proliferation and migration. Intranasal administration of NEO100 in mice with GSC-derived intracranial tumors led to a decrease in tumor progression and a 32% increase in overall survival. Immunostaining studies showed that NEO100 induces apoptosis and reduces GSC invasion in vivo.CONCLUSIONSNEO100 could have significant value targeting GSCs and could be used for GBM therapy as either monotherapy or a coadjuvant therapy during temozolomide rest cycles.
APA, Harvard, Vancouver, ISO, and other styles
8

Kutyła, Mateusz, Aleksandra Maciejczyk, Mariusz Trytek, and Joanna Jakubowicz-Gil. "Biocatalytic synthesis of terpene esters and their biological activity in human glioma cells." Current Pharmaceutical Biotechnology 22 (July 12, 2021). http://dx.doi.org/10.2174/1389201022666210712094925.

Full text
Abstract:
Background: Gliomas are highly malignant brain tumors with high resistance to chemotherapy. Therefore, investigations of new therapeutic molecules with high anti-glioma activity are of great importance. Objective: In this work, biocatalytic esterification of terpene alcohols with proven anti-cancer activity was performed to enhance their potency to induce cell death in human glioblastoma multiforme T98G and anaplastic astrocytoma MOGGCCM cell lines in vitro. Method and Results: We used primary terpene alcohols and carboxylic acids with a length of two to nine carbon atoms. The structure of the drinks influenced the esterification efficiency, which decreased in the following order: monocyclic > linear > bicyclic. Terpene alcohols and their esters only induced apoptotic cell death, which is highly desirable from a therapeutic point of view but did not induce autophagy and necrosis. The esterification of perillyl alcohol with butyric acid caused a 4-fold increase in cell death induction in the T98G line. Citronellol valerate, caprylate, and pelargonate and myrtenol butyrate, caprylate, and pelargonate also showed higher activity than their alcohol precursors. Conclusion: We have herein shown that esterification of natural alcohols by biocatalysis can improve the activity for other compounds investigated for their anti-glioma activity.
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Chemotherapy. Perillyl alcohol"

1

O'Brien, Zihong. "Pharmacokinetics, in vitro absorption and metabolism of perillyl alcohol a chemopreventive and chemotherapeutic agent /." Columbus, Ohio : Ohio State University, 2004. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1078118089.

Full text
Abstract:
Thesis (Ph. D.)--Ohio State University, 2004.
Title from first page of PDF file. Document formatted into pages; contains xxxiii, 278 p.; also includes graphics. Includes abstract and vita. Advisor: Kenneth Chan, Dept. of Pharmacy. Includes bibliographical references (p. 266-278).
APA, Harvard, Vancouver, ISO, and other styles
2

Aedo, Jenny Rosario Niño de Guzman. "Atividade de álcool, aldeído e ácido perílico contra L. (L.) major e L. (L.) amazonensis." Universidade de São Paulo, 2007. http://www.teses.usp.br/teses/disponiveis/42/42135/tde-09012008-161146/.

Full text
Abstract:
Propriedades leishmanicidas têm sido atribuídas a vários terpenos, que são compostos encontrados em plantas. Dentre esses está o limoneno, um monoterpeno presente principalmente em frutas cítricas. Em plantas e no fígado de mamíferos, o limoneno é convertido a alcool perílico (POH), aldeído perílico (PCO) e ácido perílico (PCOOH). Tanto o limoneno como seus derivados apresentam propriedades antimicrobianas e antitumorais. Neste estudo avaliamos a atividade dos derivados do limoneno para o tratamento de leishmaniose. As IC50 para POH, PCO e PCOOH foram determinadas para L. (L.) major e L. (L.) amazonensis. Demonstramos que esses compostos são citotóxicos para macrófagos, em concentrações semelhantes às efetivas contra os parasitas. Avaliação da toxicidade in vivo não evidenciou efeitos colaterais. Não houve resposta clínica à administração de POH ou PCO em camundongos infectados. A associação de POH e PCO por via intraperitoneal foi capaz de retardar a progressão da doença em camundongos infectados com L. (L.) amazonensis.
Leishmanicidal properties have been ascribed to several terpenes. Limonene is a monoterpene found mainly in citric fruits. In plants and in mammalian liver, limonene is converted to perillyl alcohol (POH), perillyl aldehyde (PCO) and perillyl acid (PCOOH). Limonene and its derivatives possess antimicrobial and antineoplasic properties. In this study we evaluated the activity of POH, PCO and PCOOH for the treatment of leishmaniasis. The inhibitory concentrations for 50% of the parasites (IC50) were determined for L. (L) major and L. (L.) amazonensis. We have shown that these drugs are toxic for macrophages, in concentrations in the same range as the effective ones against parasites. The in vivo toxicity evaluation did not show collateral effects in mice. There was no clinical response to the administration of POH or PCO to infected mice. The combination of POH e PCO by the intraperitoneal route was able to delay the disease progression in mice infected with L. (L.) amazonensis.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Chemotherapy. Perillyl alcohol"

1

Fonseca, Clovis. "Abstract B49: Perillyl alcohol: Dynamic interactions with the lipid bilayer and implications for long-term inhalational chemotherapy for gliomas." In Abstracts: AACR International Conference held in cooperation with the Latin American Cooperative Oncology Group (LACOG) on Translational Cancer Medicine; May 4-6, 2017; São Paulo, Brazil. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1557-3265.tcm17-b49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography